David Musicant, DO
Family Medicine · Tucson, AZNPI 1831177112
Payments from drug & device makers
Across 105 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$275
- Novo Nordisk$215
- Bard Peripheral Vascular, Inc.$136
- Sanofi-aventis U.S. LLC$136
- GSK$125
- Pfizer$121
- plus $580 from 10 others
What the payments were for
- Food & beverage$1,581100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $275 |
| Novo Nordisk | 18 | $215 |
| Bard Peripheral Vascular, Inc. | 1 | $136 |
| Sanofi-aventis U.S. LLC | 9 | $136 |
| GSK | 12 | $125 |
| Pfizer | 12 | $121 |
| Lilly USA, LLC | 10 | $120 |
| Johnson & Johnson | 14 | $117 |
| Amgen | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $54 |
| Boehringer Ingelheim | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Merck | 3 | $35 |
| Radius Health, Inc. | 1 | $20 |
| AbbVie | 1 | $16 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,587 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 83 | $99,074 |
| EliquisApixaban | 92 | $86,080 |
| JardianceEmpagliflozin | 44 | $79,851 |
| OzempicSemaglutide | 32 | $65,651 |
| FarxigaDapagliflozin Propanediol | 38 | $51,733 |
| XareltoRivaroxaban | 26 | $38,790 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $37,392 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $25,301 |
| TrulicityDulaglutide | 14 | $23,613 |
| Spiriva RespimatTiotropium Bromide | 24 | $20,020 |
| ProliaDenosumab | 11 | $19,732 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $19,031 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $14,797 |
| UbrelvyUbrogepant | 11 | $13,229 |
| Gabapentin | 380 | $9,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta | $50 | $114,61095 claims |
| MerckJanuvia | $35 | $99,07483 claims |
| PfizerEliquis | $121 | $86,08092 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $125 | $81,72498 claims |
| Novo NordiskOzempic, Levemir | $215 | $68,46346 claims |
| AstraZenecaFarxiga, Symbicort | $275 | $59,39164 claims |
| Johnson & JohnsonXarelto | $117 | $38,79026 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $120 | $27,64426 claims |
| AbbVieUbrelvy, Creon | $16 | $21,19722 claims |
| AmgenProlia | $111 | $19,73211 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $136 | $18,75138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.